1-[(6Z,9Z,12Z)-octadecatrienoyl]-2-[(15Z)-tetracosenoyl]-sn-glycero-3-phosphocholine

Metabolite details

Identifier

LQQRQYIGEYFSIG-UWESVXFQSA-N

InChI Key

LQQRQYIGEYFSIG-UWESVXFQSA-N

IUPAC name

(2R)-3-{[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyl]oxy}-2-{[(15Z)-tetracos-15-enoyl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate

Preferred name

1-[(6Z,9Z,12Z)-octadecatrienoyl]-2-[(15Z)-tetracosenoyl]-sn-glycero-3-phosphocholine

INN name

—

Synonym

PC(18:3(6Z,9Z,12Z)/24:1(15Z))

ChEBI

CHEBI:86422

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Hfq Regulates Efflux Pump Expression and Purine Metabolic Pathway to Increase the Trimethoprim Resistance in Aeromonas veronii
• IDH1 Mutations Induce Organelle Defects Via Dysregulated Phospholipids (CSHpos)
• Physiological extremes of the human blood metabolome: A metabolomics analysis of highly glycolytic, oxidative, and anabolic athletes
• Lipidomic Changes in the Liver of Beagle Dogs Associated with Toxocara canis Infection
• Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19
• LION-web validation lipidomics experiments (FA-incorporation, membrane fluidty)

Observed in differential profiles

• Wild_type_vs_hfq
• IDH1R132C_U251_ER_Untreated_vs_IDH1WT_U251_ER_Untreated
• Control_Baseline_vs_Control_Post-Exercise
• Control_12h_vs_Toxocara canis_12h
• Mild_vs_Severe
• BSA_Control_vs_AA